Just a quick note on a topic that keeps catching my attention: China. Three interesting things have come up in the last month:
- Organogenesis signs a distribution deal with China’s National Tissue Engineering Center, with the potential to expand into manufacturing and joint product development activities.
- WuXi Pharmatech purchases contract organization Apptec to gain a US footprint and expertise in biologics.
- Regenerative Medicine venture capital firm Toucan Capital has two positions open that require both an advanced life science degree and fluency in Chinese – I wonder where they are looking to invest their next round of funding?
With the US dollar so low and the Chinese markets so hot, it is highly possible we see even more investment from Chinese firms in US regenerative medicine companies as we are seeing in other industries. But I wonder how much more US-based capital will make it into China?
This blog is about the technology behind Regenerative Medicine - including, but not limited to, stem cells therapies, biomaterial-based devices, as well as tissue engineered products.
My name is Jon Rowley. I have been in the Regenerative Medicine field since 1994 (undergraduate research), and have my PhD in Biomedical Engineering from the University of Michigan in Biomedical Engineering. I am currently an employee of Aastrom Biosciences, an adult autologous cell therapy company. You can see my professional creds at: http://www.linkedin.com/myprofile?trk=tab_pro
Important Note: Absolutely everything posted in this blog is my personal opinion and is in no way the opinion of my employer, Aastrom Biosciences, or approved by anyone before it is posted. No warranties or other guarantees will be offered as to the quality of the opinions or anything else offered here.
This entry was posted in Regenerative Medicine
. Bookmark the permalink
Pingback: Regenerative medicine progress in regions | Stem Cell Assays